-
Study aim
-
Determining the effect of Antonex on reducing the pain of substance-dependent patients compared to oxygen therapy
-
Design
-
A clinical trial with the control group, with parallel groups, randomized phase 3 in 60 patients. The rand function of Excel software was used for randomization.
-
Settings and conduct
-
The study will be conducted at Hazrat Rasool Akram Hospital in Tehran. A person who consumes drugs according to his habit of consumption two times in the morning and the evening, the pain of his drug withdrawal symptoms starts at these times. Therefore, the person undergoing treatment will be exposed to Entonex according to the prescribed dose. The intensity of patients' physical pain will be measured according to VAS criteria. This pain scale represents a 10-cm line printed on a piece of paper with markers at each end, with “no pain” at one end and “worst pain” or “indescribable pain” at the other end. The person puts a cross X on the line to indicate the intensity of their pain.
-
Participants/Inclusion and exclusion criteria
-
Patients with a history of drug abuse, such as opium, opium sap, burnt sap, heroin and its derivatives, methadone, morphine, buprenorphine
-
Intervention groups
-
The first group will be treated with inhalation intoxication medicine (in the form of 80% oxygen + 20% nitrous oxide) for 10 days through the connecting tube. Every day, the first 15 minutes of Entonex with the prescribed dose to relieve pain and 30 minutes of oxygen to clean the lungs, remove withdrawal symptoms, and re-inhale Entonex for 5 minutes and then 10 minutes of oxygen, for a total of 60 minutes. It will take a long time. For the second group, oxygen therapy will be prescribed daily for 60 minutes.
-
Main outcome variables
-
Severity of pain experienced as a result of drug withdrawal syndrome